Pfizer PFE
US equityMarket cap rank #116Drug Manufacturers - GeneralCAR-T TherapyInfectious DiseaseCancer Research
$29.39 −$0.06 (-0.20%)
Pre-market · Nov 9, 4:50 am ET · After hours $29.35 -0.14%
Open$29.07
Prev close$29.45
Day range$28.54 – $29.43
Volume48.32M
Market cap$167.52B
P/E (TTM)42.0
Dividend yield5.85%
PFE Stock News
Headlines matching Pfizer or the PFE ticker, most recent first.
- Dow Jones Top Company Headlines at 9 PM ET: Amazon Pauses Operations With 21 Air After Miami Crash | Pfizer ...
- Pfizer (PFE.US) Sees Signs of Recovery! New Drug Revenue Surges 18%, but Patent Cliff Remains the Biggest Challenge Positive
- Pfizer, BioNTech, and Moderna sought to have Bayer's Monsanto mRNA patent lawsuit dismissed, but the judge rejected their motion. Negative
- BridgeBio (BBIO.US) cardiac therapy acoramidis outperforms Pfizer’s (PFE.US) competitor drug in real-world study
- Bernstein Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $29
- Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $28
- Pfizer (PFE.US) to share overseas price-hike gains with U.S. government: "Most-Favored-Nation" contract exposed, while over twenty deals remain confidential Positive
- HSBC Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $30 Positive
- Guggenheim Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $31 Negative
- Argus Research Maintains Pfizer(PFE.US) With Buy Rating
- DZ BANK AG Maintains Pfizer(PFE.US) With Buy Rating
- Cantor Fitzgerald Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $27
- Scotiabank Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $30
- Bernstein Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $29 Negative
- BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $30
No comments yet — be the first to weigh in on PFE.
Sign in to join the discussion.